Ribbon Blender Model 42N-270 Increases Performance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ribbon Blender Model 42N-270 Increases Performance


Pharmaceutical Technology
Volume 38, Issue 1, pp. 16
The Ribbon Blender Model 42N-270 has a maximum working capacity of 270 cu.ft. and a full holding capacity of 300 cu.ft. The stainless steel wetted parts are polished to 150-grit finish for cleanability. The gasketed three-piece cover, safety grating, and pneumatically-operated 10” knife gate valve are all designed to facilitate ingredient charging and dust-tight operation. The double ribbon agitator is fabricated to produce a well-balanced axial and radial flow of powders while holding tightly-controlled clearances between the trough. The solid agitator shaft is driven to 20 rpm by a 100 HP TEFC motor.  All Ross Ribbon Blenders are equipped with a direct drive gear motor for improved performance and lower maintenance. With Ross-supplied controls, users receive a production-ready blender and benefit from electronic speed control, soft-start capabilities, and overload protection without any wiring hassles.

Charles Ross & Son Company

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here